| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/JM00037A002 |
| P698 | PubMed publication ID | 8201587 |
| P2093 | author name string | Batchelor KW | |
| Charifson PS | |||
| Henke BR | |||
| Lubahn DB | |||
| Momtahen TM | |||
| Moore LB | |||
| Oliver BB | |||
| Sauls HR | |||
| Triantafillou JA | |||
| Willson TM | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| P304 | page(s) | 1550-1552 | |
| P577 | publication date | 1994-05-01 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats | |
| P478 | volume | 37 |
| Q35596991 | A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs). |
| Q47825566 | A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. |
| Q43807588 | Activity of a tamoxifen-raloxifene hybrid ligand for estrogen receptors at an AP-1 site |
| Q38430208 | Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells. |
| Q58591392 | Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain |
| Q43194866 | Anti-breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions |
| Q43984020 | Characterization of selective estrogen receptor modulator (SERM) activity in two triarylethylene oxybutyric acids |
| Q34047079 | Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs). |
| Q26825584 | Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer |
| Q64107217 | Development of novel and safer anti-breast cancer agents, SS1020 and SS5020, based on a fundamental carcinogenic research |
| Q43612204 | Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites |
| Q33207350 | Discovery of novel nuclear receptor modulating ligands: an integral role for peptide interaction profiling |
| Q44454227 | Endometrial effects of selective estrogen receptor modulators (SERMs) on estradiol-responsive gene expression are gene and cell-specific |
| Q41160144 | Environmental estrogens: effects on cholesterol lowering and bone in the ovariectomized rat. |
| Q37339491 | Estrogen Receptor Ligands: A Review (2013-2015). |
| Q35016384 | Estrogen receptor β ligands: recent advances and biomedical applications. |
| Q41066367 | Estrogenic tamoxifen derivatives: categorization of intrinsic estrogenicity in MCF-7 cells |
| Q46305030 | Exposure to 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDT) in relation to bone mineral density and rate of bone loss in menopausal women |
| Q89586804 | GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models |
| Q43641502 | Identification of new triarylethylene oxyalkanoic acid analogues as bone selective estrogen mimetics |
| Q36646003 | Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alpha |
| Q34652138 | Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis |
| Q38719706 | Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer |
| Q50246986 | Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation. |
| Q50851021 | Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently? |
| Q36450456 | Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer |
| Q34132645 | Progress in the prevention of breast cancer: concept to reality |
| Q53564161 | Rational Design of a Boron-Modified Triphenylethylene (GLL398) as an Oral Selective Estrogen Receptor Downregulator. |
| Q57172011 | Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health |
| Q73444764 | Synthesis and estrogenic activities of novel 7-thiosubstituted estratriene derivatives |
| Q52576554 | Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive. |
| Q40639802 | Target specificity of selective estrogen receptor modulators within human endometrial cancer cells |
| Q33730355 | The Molecular Pharmacology of SERMs |
| Q99356786 | The Quest for Orally Bioavailable Selective Estrogen Receptor Degraders (SERDs) |
| Q34688511 | The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators |
| Q36558133 | The nuclear receptor superfamily and drug discovery |
| Q34534031 | The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. |
Search more.